Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA; School of Medicine, Shanghai Jiao Tong University, China.
J Photochem Photobiol B. 2021 Feb;215:112109. doi: 10.1016/j.jphotobiol.2020.112109. Epub 2021 Jan 21.
As antimicrobial resistance continues to threaten the efficacy of conventional antibiotic therapy, it is paramount that we investigate innovative approaches to treat infectious diseases. In this study, we investigated the antimicrobial capabilities of the innovative combination of antimicrobial blue light (aBL; 405 nm wavelength) with the Pseudomonas aeruginosa pigment pyocyanin against methicillin resistant Staphylococcus aureus (MSRA. We explored the effects of different radiant exposures of aBL and increasing concentrations of pyocyanin against planktonic cells and those within biofilms. In addition, we investigated the effect of the aBL/pyocyanin on the endogenous staphyloxanthin pigment, as well as the role of hydrogen peroxide and singlet oxygen scavenging in the efficacy of this combination. Lastly, we investigated the potential for the aBL/pyocyanin to reduce the MRSA burden within a proof-of-principle mouse abrasion infection model. We found pyocyanin to be a powerful potentiator of aBL activity under all in vitro conditions tested. In addition, we serendipitously discovered the capability of the aBL/pyocyanin combination to bleach staphyloxanthin within colonies of MRSA. Furthermore, we established that singlet oxygen is an important mediator during combined aBL/pyocyanin exposure. Moreover, we found that the combination of aBL and pyocyanin could significantly reduce the viability of MRSA within a proof-of-principle early onset MRSA skin abrasion infection. Exposure to the treatment did not have deleterious effects on skin tissue. In conclusion, the combination of aBL and pyocyanin represents a potentially powerful therapeutic modality for the treatment of infections caused by MRSA.
随着抗菌药物耐药性继续威胁常规抗生素治疗的疗效，我们必须研究治疗感染性疾病的创新方法。在这项研究中，我们研究了抗菌蓝光（aBL；405nm 波长）与铜绿假单胞菌色素绿脓菌素联合使用对耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌能力。我们探讨了不同的 aBL 辐射暴露和增加的绿脓菌素浓度对浮游细胞和生物膜内细胞的影响。此外，我们研究了 aBL/绿脓菌素对内源性甲萘醌色素的影响，以及过氧化氢和单线态氧清除在这种联合作用中的作用。最后，我们研究了 aBL/绿脓菌素在原理验证小鼠擦伤感染模型中降低 MRSA 负担的潜力。我们发现绿脓菌素在所有测试的体外条件下都是 aBL 活性的强大增效剂。此外，我们偶然发现了 aBL/绿脓菌素组合在 MRSA 菌落中漂白甲萘醌的能力。此外，我们确定单线态氧是联合 aBL/绿脓菌素暴露时的重要介质。此外，我们发现 aBL 和绿脓菌素的组合可以显著降低原理验证早期发病 MRSA 皮肤擦伤感染中 MRSA 的活力。暴露于该治疗不会对皮肤组织产生有害影响。总之，aBL 和绿脓菌素的组合代表了治疗由 MRSA 引起的感染的一种潜在强大的治疗方法。
